Combined chemotherapeutic and photodynamic treatment on human bladder cells by hematoporphyrin-platinum(II) conjugates

Cancer Letters

Volumn 203, Issue 2, 2004, Pages 171-180

  Lottner, Christian ^a   Knuechel, Ruth ^a   Bernhardt, Guenther ^a   Brunner, Henri ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Bladder cancer; Chemotherapy; Photodynamic therapy; Porphyrin platinum conjugates; Synergistic effect

Indexed keywords

1,2 DIAMINOCYCLOHEXANE[7,12 BIS[1 (1,4,7 TRIOXAOCTYL)ETHYL] 3,8,13,17 TETRAMETHYLPORPHYRIN 2,18 DIPROPIONATO]PLATINUM; 1,2 DIAMINOCYCLOHEXANE[7,12 BIS[1 (POLYETHYLENEGLYCOL 750 MONOMETHYL ETHER 1 YL)ETHYL] 3,8,13,17 TETRAMETHYLPORPHYRIN 2,18 DIPROPIONATO]PLATINUM; 7,12 BIS[1 (1,4,7 TRIOXAOCTYL)ETHYL] 3,8,13,17 TETRAMETHYLPORPHYRIN 2,18 DIPROPIONIC ACID; 7,12 BIS[1 (POLYETHYLENEGLYCOL 750 MONOMETHYL ETHER 1 YL)ETHYL] 3,8,13,17 TETRAMETHYLPORPHYRIN 2,18 DIPROPIONIC ACID; ANTINEOPLASTIC AGENT; CISPLATIN; DIAMMINE[7,12 BIS[1 (1,4,7 TRIOXAOCTYL)ETHYL] 3,8,13,17 TETRAMETHYLPORPHYRIN 2,18 DIPROPIONATO]PLATINUM; DIAMMINE[7,12 BIS[1 (POLYETHYLENEGLYCOL 750 MONOMETHYL ETHER 1 YL)ETHYL] 3,8,13,17 TETRAMETHYLPORPHYRIN 2,18 DIPROPIONATO]PLATINUM; HEMATOPORPHYRIN DERIVATIVE; OXALIPLATIN; PLATINUM DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; COMPLEX FORMATION; CONJUGATE; CONTROLLED STUDY; CYTOSTASIS; CYTOTOXICITY; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; HUMAN; HUMAN CELL; PHOTODYNAMIC THERAPY; PHOTOTOXICITY; PRIORITY JOURNAL; STRUCTURE ANALYSIS; UROTHELIUM;

EID: 0347355444     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2003.09.001     Document Type: Article

References (16)

1. Culine S. The present and future of combination chemotherapy in bladder cancer. Semin. Oncol. 29:2002;32-39.
2. Soulié P., Raymond E., Brienza S., Cvitkovic E. Oxaliplatin: the first DACH platinum in clinical practice. Bull. Cancer. 84:1997;665-673.
3. Raymond E., Chaney S.G., Taamma A., Cvitkovic E. Oxaliplatin: a review of preclinical and clinical studies. Ann. Oncol. 9:1998;1053-1071.
4. Cvitkovic E. Ongoing and unsaid on oxaliplatin: the hope. Br. J. Cancer. 77:1998;8-11.
5. Dougherty T.J., Gomer C.J., Henderson B.W., Jori G., Kessel D., Korbelik M., Moan J., Peng Q. Photodynamic therapy. J. Natl Cancer Inst. 90:1998;889-905.
6. Sharman W.M., Allen C.M., van Lier J.E. Photodynamic therapeutics: basic principles and clinical applications. Drug Discovery Today. 4:1999;507-517.
7. Lottner C., Bart K.-C., Bernhardt G., Brunner H. Hematoporphyrin-derived soluble porphyrin-platinum conjugates with combined cytotoxic and phototoxic antitumor activity. J. Med. Chem. 45:2002;2064-2078.
8. O'Toole C.M. Webber M.M., Sikeley L. Human bladder cancer cell lines: HLA Class I and Class II antigen expression and susceptibility to cytostatic and cytolytic effects in vitro. In vitro models for cancer research. vol. IV:1986;103-125 CRC Press, Boca Raton, FL, USA.
9. Petzoldt J.L., Leigh I.M., Duffy P.G., Sexton C., Masters J.R. Immortalisation of human urothelial cells. Urol. Res. 23:1995;377-380.
10. Reile H., Birnböck H., Bernhardt G., Spruß T., Schönenberger H. Computerized determination of growth kinetic curves and doubling times from cells in microculture. Anal. Biochem. 187:1990;262-267.
11. Bernhardt G., Reile H., Birnböck H., Spruß T., Schönenberger H. Standardized kinetic microassay to quantitate differential chemosensitivity based on proliferative activity. J. Cancer Res. Clin. Oncol. 118:1992;35-43.
12. Spruß T., Bernhardt G., Schickaneder E., Schönenberger H. Different response of murine and human mammary tumor models to a series of diastereoisomeric [1,2-bis(difluorophenyl)ethylenediamine]dichloroplatinum(II) complexes. J. Cancer Res. Clin. Oncol. 117:1991;435-443.
13. Bernhardt G., Koch M., Spruß T., Gust R., Krauser R., Schlemmer R., Hollstein M., Lux F., Schönenberger H. meso-1,2-Bis(2,6-dichloro-4- hydroxyphenyl)ethylenediamine]sulfatoplatinum(II)-pharmacokinetic studies. Arch. Pharm. Pharm. Med. Chem. 332:1999;195-200.
14. Karrer S., Szeimies R.-M., Ebert A., Fickweiler S., Abels C., Bäumler W., Landthaler M. Dose-dependent photodynamic effects of 9-Acetoxy-2,7,12,17- tetrakis-(β-methoxyethyl)-porphycene in vitro. Lasers Med. Sci. 12:1997;307-312.
15. Hornung R., Fehr M.K., Monti-Frayne J., Krasieva T.B., Tromberg B.J., Berns M.W., Tadir Y. Highly selective targeting of ovarian cancer with the photosensitizer PEG-m-THPC in a rat model. Photochem. Photobiol. 70:1999;624-629.
16. Rovers J.P., Saarnak A.E., de Jode M., Sterenborg H.J., Terpstra O.T., Grahn M.F. Biodistribution and bioactivity of tetra-pegylated meta-tetra(hydroxyphenyl)chlorin compared to native meta-tetra(hydroxyphenyl) chlorin in a rat liver tumor model. Photochem. Photobiol. 71:2000;210-217.